Heiko M. Schöder
#163,920
Most Influential Person Now
Heiko M. Schöder's AcademicInfluence.com Rankings
Heiko M. Schöderengineering Degrees
Engineering
#7181
World Rank
#8544
Historical Rank
Cybernetics
#153
World Rank
#159
Historical Rank
Biomedical Engineering
#699
World Rank
#711
Historical Rank
Download Badge
Engineering
Heiko M. Schöder's Degrees
- PhD Biomedical Engineering Stanford University
- Masters Biomedical Engineering Stanford University
- Bachelors Biomedical Engineering Stanford University
Why Is Heiko M. Schöder Influential?
(Suggest an Edit or Addition)Heiko M. Schöder's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Clinical translation of an ultrasmall inorganic optical-PET imaging nanoparticle probe (2014) (538)
- 68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0 (2017) (480)
- Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. (2005) (451)
- Head and neck cancer: clinical usefulness and accuracy of PET/CT image fusion. (2004) (397)
- Patterns of (18)F-FDG uptake in adipose tissue and muscle: a potential source of false-positives for PET. (2003) (379)
- Positron emission tomography for prostate, bladder, and renal cancer. (2004) (332)
- Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma. (2010) (309)
- Diagnostic and Prognostic Value of [18F]Fluorodeoxyglucose Positron Emission Tomography for Recurrent Head and Neck Squamous Cell Carcinoma (2002) (287)
- 18F-FDG PET/CT for detecting nodal metastases in patients with oral cancer staged N0 by clinical examination and CT/MRI. (2006) (254)
- Clinical Utility of 18F-FDG PET/CT in Assessing the Neck After Concurrent Chemoradiotherapy for Locoregional Advanced Head and Neck Cancer (2008) (247)
- Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study. (2008) (235)
- US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. (2016) (224)
- Brown adipose tissue is associated with cardiometabolic health (2021) (206)
- PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study. (2015) (206)
- Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. (2019) (198)
- PET/CT in oncology: integration into clinical management of lymphoma, melanoma, and gastrointestinal malignancies. (2004) (196)
- EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT) (2019) (196)
- 2-[18F]Fluoro-2-Deoxyglucose Positron Emission Tomography for the Detection of Disease in Patients with Prostate-Specific Antigen Relapse after Radical Prostatectomy (2005) (187)
- PET Monitoring of Therapy Response in Head and Neck Squamous Cell Carcinoma (2009) (177)
- Effects of long-term smoking on myocardial blood flow, coronary vasomotion, and vasodilator capacity. (1998) (175)
- Deep-inspiration breath-hold PET/CT of the thorax. (2007) (174)
- Positron emission imaging of head and neck cancer, including thyroid carcinoma. (2004) (168)
- Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy. (2005) (166)
- PET/CT: a new imaging technology in nuclear medicine (2003) (166)
- Diagnostic Accuracy of 18F-FDG PET in Restaging Patients with Medullary Thyroid Carcinoma and Elevated Calcitonin Levels (2007) (162)
- 18F-FDG PET/CT Metabolic Tumor Volume and Total Lesion Glycolysis Predict Outcome in Oropharyngeal Squamous Cell Carcinoma (2012) (160)
- Classification and evaluation strategies of auto‐segmentation approaches for PET: Report of AAPM task group No. 211 (2017) (149)
- Screening for cancer with PET and PET/CT: potential and limitations. (2007) (141)
- Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in bladder cancer. (2010) (141)
- Phase and amplitude binning for 4D-CT imaging (2006) (140)
- Diagnostic and prognostic value of [(18)F]fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. (2002) (136)
- The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL). (2008) (132)
- Effect of Whole-Body 18F-FDG PET Imaging on Clinical Staging and Management of Patients with Malignant Lymphoma (2001) (130)
- Prognostic Value of Baseline [18F] Fluorodeoxyglucose Positron Emission Tomography and 99mTc-MDP Bone Scan in Progressing Metastatic Prostate Cancer (2010) (126)
- Diagnostic accuracy and prognostic value of 18F-FDG PET in Hürthle cell thyroid cancer patients. (2006) (126)
- Hybrid imaging (SPECT/CT and PET/CT): improving therapeutic decisions. (2009) (126)
- L-Arginine normalizes coronary vasomotion in long-term smokers. (1999) (125)
- Imaging for Staging and Response Assessment in Lymphoma. (2015) (124)
- 68 Ga-PSMA PET / CT : Joint EANM and SNMMI procedure guideline for prostate cancer imaging : version 1 . 0 (2017) (123)
- A prospective evaluation of the utility of 2‐deoxy‐2‐[18F]fluoro‐D‐glucose positron emission tomography and computed tomography in staging locally advanced gastric cancer (2012) (122)
- Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study. (2010) (122)
- Prospective trial incorporating pre-/mid-treatment [18F]-misonidazole positron emission tomography for head-and-neck cancer patients undergoing concurrent chemoradiotherapy. (2009) (118)
- Pharmacokinetic Assessment of the Uptake of 16β-18F-Fluoro-5α-Dihydrotestosterone (FDHT) in Prostate Tumors as Measured by PET (2010) (110)
- Radiation dosimetry of 18F-FDG PET/CT: incorporating exam-specific parameters in dose estimates (2016) (105)
- 18F-FDG PET/CT for Monitoring of Ipilimumab Therapy in Patients with Metastatic Melanoma (2018) (103)
- Coronary artery disease after radiation therapy for Hodgkin's lymphoma: coronary CT angiography findings and calcium scores in nine asymptomatic patients. (2008) (103)
- Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma. (2017) (101)
- Ga-PSMA PET / CT : Joint EANM and SNMMI procedure guideline for prostate cancer imaging : version 1 . 0 (2017) (101)
- Deep-Inspiration Breath-Hold PET/CT: Clinical Findings with a New Technique for Detection and Characterization of Thoracic Lesions (2007) (101)
- Phase III Randomized Study of R-CHOP Versus DA-EPOCH-R and Molecular Analysis of Untreated Diffuse Large B-Cell Lymphoma: CALGB/Alliance 50303 (2016) (101)
- Noninvasive assessment of tumor microenvironment using dynamic contrast-enhanced magnetic resonance imaging and 18F-fluoromisonidazole positron emission tomography imaging in neck nodal metastases. (2010) (99)
- Split-dose technique for FDG PET/CT-guided percutaneous ablation: a method to facilitate lesion targeting and to provide immediate assessment of treatment effectiveness. (2013) (99)
- EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer. (2018) (98)
- Schöder H, Noy A, Gönen M, et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin’s lymphoma. J Clin Oncol. 23: 4643-4651 (2005) (95)
- The Effect of Posttherapy 131I SPECT/CT on Risk Classification and Management of Patients with Differentiated Thyroid Cancer (2010) (94)
- Characterization of T-cell lymphomas by FDG PET/CT. (2010) (94)
- Noninvasive Assessment of Coronary Microcirculatory Function in Postmenopausal Women and Effects of Short-Term and Long-Term Estrogen Administration (2002) (92)
- Tumor metabolism and perfusion in head and neck squamous cell carcinoma: pretreatment multimodality imaging with 1H magnetic resonance spectroscopy, dynamic contrast-enhanced MRI, and [18F]FDG-PET. (2012) (90)
- Clinical implications of different image reconstruction parameters for interpretation of whole-body PET studies in cancer patients. (2004) (89)
- The role of imaging in the detection of prostate cancer local recurrence after radiation therapy and surgery (2008) (89)
- Pharmacokinetic Analysis of Hypoxia 18F-Fluoromisonidazole Dynamic PET in Head and Neck Cancer (2010) (88)
- Prevalence of myocardial viability as detected by positron emission tomography in patients with ischemic cardiomyopathy. (1999) (84)
- Pediatric bone sarcoma: diagnostic performance of ¹⁸F-FDG PET/CT versus conventional imaging for initial staging and follow-up. (2015) (81)
- Pharmacokinetics, Biodistribution, and Radiation Dosimetry for 89Zr-Trastuzumab in Patients with Esophagogastric Cancer (2018) (78)
- PET for Staging in Rhabdomyosarcoma: An Evaluation of PET as an Adjunct to Current Staging Tools (2007) (74)
- CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. (2018) (72)
- Positron Emission Tomography/Computed Tomography–Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer (2017) (72)
- Five-Year Follow-up of SWOG S0816: Limitations and Values of a PET-Adapted Approach for Stage III/IV Hodgkin Lymphoma. (2019) (71)
- Advances in imaging in the postoperative patient with a rising prostate-specific antigen level. (2003) (71)
- Thyroid cancer--indications and opportunities for positron emission tomography/computed tomography imaging. (2011) (71)
- Prospective evaluation of MRI, ¹¹C-acetate PET/CT and contrast-enhanced CT for staging of bladder cancer. (2012) (70)
- Prognostic value of baseline metabolic tumor volume measured on 18F-fluorodeoxyglucose positron emission tomography/computed tomography in melanoma patients treated with ipilimumab therapy (2018) (68)
- 18F-FDG PET/CT for the Prediction and Detection of Local Recurrence After Radiofrequency Ablation of Malignant Lung Lesions (2010) (67)
- Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma. (2016) (67)
- Respiration artifacts in whole-body 18F-FDG PET/CT studies with combined PET/CT tomographs employing spiral CT technology with 1 to 16 detector rows (2005) (64)
- Evaluation of romidepsin for clinical activity and radioactive iodine reuptake in radioactive iodine-refractory thyroid carcinoma. (2013) (61)
- Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET. (2011) (61)
- Target volume delineation in oropharyngeal cancer: impact of PET, MRI, and physical examination. (2010) (60)
- Nuclear Medicine Operations in the Times of COVID-19: Strategies, Precautions, and Experiences (2020) (60)
- Effect of mental stress on myocardial blood flow and vasomotion in patients with coronary artery disease. (2000) (59)
- Precision Radiotherapy: Reduction in Radiation for Oropharyngeal Cancer in the 30 ROC Trial. (2021) (57)
- 18F-fluorodeoxyglucose positron emission tomography in the staging and prognosis of T cell lymphoma (2013) (57)
- Relationship between coronary function by positron emission tomography and temporal changes in morphology by intravascular ultrasound (IVUS) in transplant recipients. (1999) (56)
- Blood flow-metabolism imaging with positron emission tomography in patients with diabetes mellitus for the assessment of reversible left ventricular contractile dysfunction. (1999) (56)
- Chimeric antigen receptor (CAR+) modified T cells targeting prostate-specific membrane antigen (PSMA) in patients (pts) with castrate metastatic prostate cancer (CMPC). (2013) (54)
- Clinical significance of unexplained abnormal focal FDG uptake in the abdomen during whole-body PET. (2004) (54)
- Prognostic Value of Interim FDG-PET in Diffuse Large Cell Lymphoma: Results from the CALGB 50303 Clinical Trial. (2020) (50)
- Advances in oncologic imaging (2012) (49)
- Effect of whole-body (18)F-FDG PET imaging on clinical staging and management of patients with malignant lymphoma. (2001) (48)
- Radiomic features of glucose metabolism enable prediction of outcome in mantle cell lymphoma (2019) (47)
- Practical Approach for Comparative Analysis of Multilesion Molecular Imaging Using a Semiautomated Program for PET/CT (2011) (47)
- Clinical Value of Combined Positron Emission Tomography/Computed Tomography Imaging in the Interpretation of 2-Deoxy-2-[F-18]fluoro-d-glucose–Positron Emission Tomography Studies in Cancer Patients (2005) (47)
- Predicting hypoxia status using a combination of contrast-enhanced computed tomography and [18F]-Fluorodeoxyglucose positron emission tomography radiomics features. (2017) (47)
- Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma (2021) (45)
- Predictive modeling of outcomes following definitive chemoradiotherapy for oropharyngeal cancer based on FDG-PET image characteristics (2013) (45)
- Metabolic Tumor Volume in Lymphoma: Hype or Hope? (2016) (44)
- Interim [18F]fluorodeoxyglucose positron emission tomography imaging in stage I–II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone? (2012) (44)
- Noncontrast perfusion single-photon emission CT/CT scanning: a new test for the expedited, high-accuracy diagnosis of acute pulmonary embolism. (2014) (43)
- Regulation of pyruvate dehydrogenase activity and glucose metabolism in post-ischaemic myocardium. (1998) (43)
- Developing imaging strategies for castration resistant prostate cancer (2011) (42)
- PET imaging for response assessment in lymphoma: potential and limitations. (2008) (41)
- The Future of Nuclear Medicine, Molecular Imaging, and Theranostics. (2020) (41)
- Evaluation of Different Methods of 18F-FDG-PET Target Volume Delineation in the Radiotherapy of Head and Neck Cancer (2008) (41)
- Initial Results with 11C-Acetate Positron Emission Tomography/Computed Tomography (PET/CT) in the Staging of Urinary Bladder Cancer (2012) (40)
- Bladder cancer: can imaging change patient management? (2008) (39)
- Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG) (2021) (39)
- Phase III Multi-Center, Prospective, Randomized Trial Comparing Single Dose 24 Gy Radiotherapy to a 3-Fraction SBRT Regimen in the Treatment of Oligometastatic Cancer. (2021) (37)
- Prospective Study of 3′-Deoxy-3′-18F-Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell Lymphoma (2016) (37)
- The value of 18F-FDG PET/CT in recurrent gynecologic malignancies prior to pelvic exenteration. (2013) (37)
- [¹⁸F]FDG-positron emission tomography coregistration with computed tomography scans for radiation treatment planning of lymphoma and hematologic malignancies. (2011) (36)
- CT in PET/CT: essential features of interpretation. (2005) (35)
- Monitoring early response to chemoradiotherapy with 18F-FMISO dynamic PET in head and neck cancer (2017) (35)
- Phase II Trial of Dose-Dense R-CHOP Followed by Risk-Adapted Consolidation with Either ICE or ICE and ASCT, Based upon the Results of Biopsy Confirmed Abnormal Interim Restaging PET Scan, Improves Outcome in Patients with Advanced Stage DLBCL. (2006) (34)
- Baseline and interim functional imaging with PET effectively risk stratifies patients with peripheral T-cell lymphoma. (2019) (34)
- Thymic extension in the superior mediastinum in patients with thymic hyperplasia: potential cause of false-positive findings on 18F-FDG PET/CT. (2007) (33)
- The relative prognostic utility of standardized uptake value, gross tumor volume, and metabolic tumor volume in oropharyngeal cancer patients treated with platinum based concurrent chemoradiation with a pre-treatment [(18)F] fluorodeoxyglucose positron emission tomography scan. (2014) (32)
- Advances in positron emission tomography applications for urologic cancers (2008) (32)
- Reporting Guidance for Oncologic 18F-FDG PET/CT Imaging (2013) (31)
- Molecular targeting of the lymphovascular system for imaging and therapy (2006) (31)
- Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study. (2019) (31)
- Molecular profiling of neuroendocrine tumours to predict response and toxicity to peptide receptor radionuclide therapy. (2020) (31)
- Molecular imaging of prostate cancer (2012) (31)
- Multiparametric Imaging of Tumor Hypoxia and Perfusion with 18F-Fluoromisonidazole Dynamic PET in Head and Neck Cancer (2017) (31)
- Clinical Utility of 18 F-FDG PET / CT in Assessing the Neck After Concurrent Chemoradiotherapy for Locoregional Advanced Head and Neck Cancer (2008) (31)
- Radiotheranostics in oncology: current challenges and emerging opportunities (2022) (30)
- A comprehensive review of imaging findings in COVID-19 - status in early 2021 (2021) (29)
- Magnetic Resonance Imaging/Positron Emission Tomography Provides a Roadmap for Surgical Planning and Serves as a Predictive Biomarker in Patients With Recurrent Gynecological Cancers Undergoing Pelvic Exenteration (2013) (29)
- Novel Approaches to Thyroid Cancer Treatment and Response Assessment. (2016) (28)
- Phase II biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas. (2021) (28)
- Brown adipose tissue is associated with healthier body fat distribution and metabolic benefits independent of regional adiposity (2021) (28)
- Regulation of myocardial blood flow response to mental stress in healthy individuals. (2000) (28)
- Feasibility of In Situ, High-Resolution Correlation of Tracer Uptake with Histopathology by Quantitative Autoradiography of Biopsy Specimens Obtained Under 18F-FDG PET/CT Guidance (2015) (27)
- 18F-Fluciclovine (18F-FACBC) PET imaging of recurrent brain tumors (2019) (27)
- The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: A combined analysis of 3 CALGB trials (2018) (27)
- Reproducibility of 18F-fluoromisonidazole intratumour distribution in non-small cell lung cancer (2016) (26)
- Clinical utility of perfusion (Q)-single-photon emission computed tomography (SPECT)/CT for diagnosing pulmonary embolus (PE) in COVID-19 patients with a moderate to high pre-test probability of PE (2020) (25)
- Prognostic Value of FDG PET/CT before Allogeneic and Autologous Stem Cell Transplantation for Aggressive Lymphoma. (2015) (24)
- The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance) (2013) (24)
- [18F]FDG-PET/CT Radiomics for Prediction of Bone Marrow Involvement in Mantle Cell Lymphoma: A Retrospective Study in 97 Patients (2020) (24)
- Initial Results of US Intergroup Trial of Response-Adapted Chemotherapy or Chemotherapy/Radiation Therapy Based on PET for Non-Bulky Stage I and II Hodgkin Lymphoma (HL) (CALGB/Alliance 50604) (2015) (24)
- Very low utility of surveillance imaging in early‐stage classic Hodgkin lymphoma treated with a combination of doxorubicin, bleomycin, vinblastine, and dacarbazine and radiation therapy (2015) (23)
- FDG-PET adapted sequential therapy with brentuximab vedotin and augmented ICE followed by autologous stem cell transplant for relapsed and refractory Hodgkin lymphoma. (2013) (23)
- Chimeric antigen receptor (CAR+) modified T cells targeting prostate specific membrane antigen (PSMA) in patients (pts) with castrate metastatic prostate cancer (CMPC). (2013) (23)
- Fundamentals of molecular imaging: rationale and applications with relevance for radiation oncology. (2008) (23)
- Reply: Would Patient Selection Based on Both Calcitonin Blood Level and Doubling Time Improve 18F-FDG PET Sensitivity in Restaging of Medullary Thyroid Cancer? (2007) (23)
- Safety and Feasibility of PARP1/2 Imaging with 18F-PARPi in Patients with Head and Neck Cancer (2020) (23)
- ABVD alone and a PET scan complete remission negates the need for radiologic surveillance in early‐stage, nonbulky Hodgkin lymphoma (2013) (22)
- Uptake of [18F]fluorodeoxyglucose in initial positron-emission tomography predicts survival in MALT lymphoma. (2018) (22)
- MRI and PET/MRI in hematologic malignancies (2019) (22)
- Pharmacokinetic Analysis of Dynamic 18F-Fluoromisonidazole PET Data in Non–Small Cell Lung Cancer (2017) (21)
- Cdk4/6 Inhibitor PD 0332991 Demonstrates Cell Cycle Inhibition Via FLT-PET Imaging and Tissue Analysis in Patients with Recurrent Mantle Cell Lymphoma (2008) (20)
- Incidental detection of concurrent extramedullary plasmacytoma and amyloidoma of the nasopharynx on [18F]fluorodeoxyglucose positron emission tomography/computed tomography. (2008) (19)
- Glucose metabolism in reperfused myocardium measured by [2-18F] 2-fluorodeoxyglucose and PET. (2000) (18)
- Baseline FDG-PET/CT detects bone marrow involvement in follicular lymphoma and provides relevant prognostic information. (2020) (18)
- Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma (2021) (18)
- Melanoma metastasis to the testis demonstrated with FDG PET/CT. (2004) (17)
- A prospective study of ¹⁸FDG-PET with CT coregistration for radiation treatment planning of lymphomas and other hematologic malignancies. (2014) (16)
- Postoperative PET/CT and target delineation before adjuvant radiotherapy in patients with oral cavity squamous cell carcinoma (2016) (16)
- Functional Imaging using Radiomic Features in Assessment of Lymphoma. (2020) (16)
- Feasibility of 18F-Fluoromisonidazole Kinetic Modeling in Head and Neck Cancer Using Shortened Acquisition Times (2016) (16)
- [18F]FACBC Imaging of recurrent gliomas: A comparison with [11C]methionine and MRI (2006) (15)
- The Effect of Posttherapy 131 I SPECT / CT on Risk Classification and Management of Patients with Differentiated Thyroid Cancer (2010) (14)
- Current status of the role of PET imaging in diffuse large B-cell lymphoma. (2015) (14)
- Non-invasive imaging prediction of tumor hypoxia: a novel developed and externally validated CT and FDG-PET-based radiomic signatures. (2020) (14)
- Prognostic significance of PET assessment of metabolic response to therapy in oesophageal squamous cell carcinoma (2015) (14)
- Pilot study of PET imaging of 124I-iodoazomycin galactopyranoside (IAZGP), a putative hypoxia imaging agent, in patients with colorectal cancer and head and neck cancer (2013) (13)
- Considerations on Integrating Prostate-Specific Membrane Antigen Positron Emission Tomography Imaging Into Clinical Prostate Cancer Trials by National Clinical Trials Network Cooperative Groups (2022) (13)
- Prostate-specific membrane antigen positron emission tomography (PSMA-PET) for local staging of prostate cancer: a systematic review and meta-analysis (2020) (13)
- 11C-Choline PET/CT in Recurrent Prostate Cancer: Retrospective Analysis in a Large U.S. Patient Series (2019) (13)
- A phase I study of a PARP1-targeted topical fluorophore for the detection of oral cancer (2020) (12)
- Overcoming the COVID-19 Crisis and Planning for the Future (2020) (12)
- Use of positron emission tomography scan response to guide treatment change for locally advanced gastric cancer: the Memorial Sloan Kettering Cancer Center experience. (2016) (12)
- The Impact of Semiautomatic Segmentation Methods on Metabolic Tumor Volume, Intensity, and Dissemination Radiomics in 18F-FDG PET Scans of Patients with Classical Hodgkin Lymphoma (2022) (11)
- Comparing the clinical performance and cost efficacy of [68Ga]Ga-PSMA-11 and [18F]PSMA-1007 in the diagnosis of recurrent prostate cancer: a Markov chain decision analysis (2021) (11)
- FDG-PET in the staging and prognosis of T-cell lymphoma. (2011) (11)
- Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[18F]FDG PET/CT external beam radiation treatment planning in lung cancer V1.0 (2022) (11)
- Fluorine-18 labeled poly (ADP-ribose) polymerase1 inhibitor as a potential alternative to 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography in oral cancer imaging. (2020) (11)
- 18F-Fluorocholine PET uptake correlates with pathologic evidence of recurrent tumor after stereotactic radiosurgery for brain metastases (2019) (11)
- EANM/SNMMI practice guideline for [18F]FDG PET/CT external beam radiotherapy treatment planning in uterine cervical cancer v1.0 (2020) (11)
- Phase I/II clinical trial of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma. (2018) (10)
- Head and Neck Cancer (2013) (10)
- Early Relapse of Follicular Lymphoma after Rituximab-Based Biologic Doublet Upfront Therapy Is Associated with Increased Risk of Death: A Combined Analysis from CALGB Studies 50402, 50701 and 50803 (Alliance) (2016) (10)
- TARC Predicts PET-Normalization and Event Free Survival in Relapsed/Refractory Hodgkin Lymphoma Patients Treated With Brentuximab Vedotin. (2015) (10)
- Safety and Early Efficacy in an Ongoing Pilot Study of Brentuximab Vedotin and AVD Chemotherapy Followed By 30 Gray Involved-Site Radiotherapy for Newly Diagnosed, Early Stage, Unfavorable Risk Hodgkin Lymphoma (2014) (10)
- A phase II study of VEGF trap (aflibercept) in patients with radioactive iodine-refractory, positron emission tomography (PET) positive thyroid carcinoma. (2010) (9)
- Imaging of CAR T-Cells in Cancer Patients: Paving the Way to Treatment Monitoring and Outcome Prediction (2019) (9)
- Correction to: 18F-Fluciclovine (18F-FACBC) PET imaging of recurrent brain tumors (2019) (9)
- First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer (2020) (9)
- Variants and Pitfalls in PET/CT Imaging of Gastrointestinal Cancers. (2021) (9)
- High Complete Response Rate Observed with Second-Line Chemo-Immunotherapy with Pembrolizumab and GVD (Gemcitabine, Vinorelbine, and Liposomal Doxorubicin) in Relapsed and Refractory Classical Hodgkin Lymphoma (2019) (9)
- Interim Positron Emission Tomography (PET) in Diffuse Large B-Cell Lymphoma: Independent Expert Nuclear Medicine Evaluation of ECOG 3404 (2008) (8)
- Solitary Extramedullary Plasmacytoma of the Cricoid Cartilage—Case Report (2017) (8)
- Positron emission tomography and magnetic resonance imaging in primary central nervous system lymphoma—a narrative review (2021) (8)
- 11C-Choline Pharmacokinetics in Recurrent Prostate Cancer (2018) (8)
- Adnexal mass secondary to extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) with associated amyloid deposition (2014) (8)
- A personalized approach using hypoxia resolution to guide curative-intent radiation dose-reduction to 30 Gy: A novel de-escalation paradigm for HPV-associated oropharynx cancers (OPC). (2017) (7)
- Metaiodobenzylguanidine imaging comes of age. A new arrow in the prognostic quiver for heart failure patients. (2010) (7)
- Long-Term Follow-up of SWOG S0816: Response-Adapted Therapy for Stage III/IV Hodgkin Lymphoma Demonstrates Limitations of PET-Adapted Approach (2018) (7)
- BASELINE METABOLIC TUMOR VOLUME IS AN INDEPENDENT PROGNOSTIC FACTOR FOR RELAPSED AND REFRACTORY HODGKIN LYMPHOMA PATIENTS RECEIVING PET‐ADAPTED SALVAGE THERAPY WITH BRENTUXIMAB VEDOTIN AND AUGMENTED ICE (2017) (7)
- CALGB 50801 (Alliance): PET adapted therapy in bulky stage I/II classic Hodgkin lymphoma (cHL). (2021) (7)
- The Prostate Cancer Clinical Trials Consortium (PCCTC) bone scan data capture tool for clinical trials using Prostate Cancer Working Group 2 (PCWG2) criteria: Effect on data accuracy and workload. (2011) (7)
- Lesion Glycolysis Predict Outcome in Oropharyngeal Squamous Cell Carcinoma (2012) (6)
- Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring (2021) (6)
- The 30 ROC trial: Precision intra-treatment imaging guiding major radiation reduction in human papillomavirus related oropharyngeal cancer. (2021) (6)
- Treadmill Exercise Inducing Mild to Moderate Ischemia Has No Significant Effect on Skeletal Muscle or Cardiac 18F-FDG Uptake and Image Quality on Subsequent Whole-Body PET Scan (2012) (6)
- Diversity of biology in castrate resistant prostate cancer (2009) (6)
- Brown Adipose Tissue is Associated with Improved Cardiometabolic Health and Regulates Blood Pressure (2020) (6)
- Cobimetinib‐induced “dropped head syndrome” and subsequent disease management in an Erdheim‐Chester patient (2019) (6)
- Prognostic value of [18F]FDG PET/CT in patients with CNS lymphoma receiving ibrutinib-based therapies (2021) (5)
- Interim FDG PET Imaging in CALGB 50203 Trial of Stage I/II Non-Bulky Hodgkin Lymphoma: Would Using Combined PET and CT Criteria Better Predict Response Than Each Test Alone?, (2011) (5)
- Galiximab, an anti-CD80 primatized monoclonal antibody, in relapsed Hodgkin lymphoma: Final results of CALGB 50602. (2010) (5)
- The Optimal Timing of Interim 18F-FDG PET in Diffuse Large B-Cell Lymphoma: An Individual Patient Data Meta-Analysis By the Petra Consortium (2019) (5)
- Impact of ComBat Harmonization on PET Radiomics-Based Tissue Classification: A Dual-Center PET/MRI and PET/CT Study (2022) (5)
- The geriatric syndrome of sarcopenia impacts allogeneic hematopoietic cell transplantation outcomes in older lymphoma patients (2020) (5)
- A Prospective Study of 18FDG-PET with CT scan Co-registration for Radiation Treatment Planning of Lymphoma and Hematologic Malignancies (2010) (5)
- Phase II Study of Pembrolizumab Plus GVD As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma (2020) (5)
- Rosai-Dorfman Disease-Utility of 18F-FDG PET/CT for Initial Evaluation and Follow-up. (2020) (5)
- Frontline Sequential Immunochemotherapy Plus Lenalidomide for Mantle Cell Lymphoma Incorporating MRD Evaluation: Phase II, Investigator-Initiated, Single-Center Study (2020) (4)
- Myocardial imaging for mitochondrial membrane potential. (2012) (4)
- SU‐D‐110‐03: A New Phantom Allowing Realistic Non‐Uniform Activity Distributions for PET Quantification (2011) (4)
- Reproducibility of F-18-FMISO intratumor distribution and texture features in NSCLC (2015) (4)
- Phase 2 study of vascular endothelial growth factor trap for the treatment of metastatic thyroid cancer (2019) (4)
- Phase III Multi-Center, Prospective Randomized Trial Comparing High Dose Single Fraction Radiation Therapy to a 3-Fraction SBRT Regimen in the Treatment of Oligometastatic Human Cancer (2018) (4)
- The probability of a positive bone scan in patients who were treated with adrogen ablasio therapy for rising PSA after radical prostatectomy. (2006) (4)
- Prognostic Value of metabolic parameters on Pretreatment F-18 FDG PET/CT in Patients with Advanced melanoma treated with Pembrolizumab (2019) (4)
- A phase I trial of sorafenib with whole brain radiotherapy (WBRT) in breast cancer patients with brain metastases and a correlative study of FLT-PET brain imaging (2021) (4)
- A pilot study of 13N-ammonia cardiac PET imaging to assess subacute cardiotoxicity following adjuvant intensity-modulated radiotherapy for locally advanced breast cancer. (2020) (4)
- A phase II study of VEGF trap in patients with radioactive iodine (RAI)-refractory thyroid carcinoma. (2011) (4)
- A Pilot Study of Brentuximab Vedotin and AVD Chemotherapy Followed By 20 Gy Involved-Site Radiotherapy in Early Stage, Unfavorable Risk Hodgkin Lymphoma (2017) (3)
- Phase I Study Combining Ibrutinib with Rituximab, Ifosfamide, Carboplatin, and Etoposide (R-ICE) in Patients with Relapsed or Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL): NCI-Cancer Therapeutics Evaluation Program (CTEP) #9588 (2016) (3)
- Imaging following thermal ablation of early lung cancers: expected post-treatment findings and tumour recurrence. (2021) (3)
- An iterative technique for lesion segmentation in PET images (2006) (3)
- Perspective paper about the joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[18F]FDG-PET/CT external beam radiation treatment planning in lung cancer (2022) (3)
- Positron Emission Tomography (PET) Response to Initial Chemotherapy and Radiation Therapy (RT) Predicts Local Control in Rhabdomyosarcoma (2011) (3)
- Interim PET Evaluation By Deauville Criteria Is an Effective Risk Stratification Tool in PTCL (2016) (3)
- Positron emission tomography after three-dimensional conformal radiation therapy for non-small cell lung cancer (2001) (3)
- Post-Treatment/Pre-operative PET Response Is Not an Independent Predictor of Outcomes for Patients With Gastric and GEJ Adenocarcinoma (2017) (3)
- Noninvasive assessment of tumor microenvironment using dynamic contrast enhanced MRI and 18 F- fluoromisonidazole PET imaging in neck nodal metastases (2010) (3)
- Reproducibility of Fluorine-18-Labeled Fluoro-Misonidazole Positron Emission Tomography (FMISO PET) in Detecting Chronic Hypoxia (CH) in Head/Neck Cancer (HNC) (2005) (3)
- CALGB 50801 (ALLIANCE): PET ADAPTED THERAPY IN BULKY STAGE I/II CLASSIC HODGKIN LYMPHOMA (CHL) (2021) (3)
- Phase I dose escalation of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and follicular lymphoma (FL). (2017) (3)
- PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0 (2023) (3)
- A Personalized Approach Using Hypoxia Resolution to Guide Curative-Intent Radiation Therapy Dose-Reduction to 30 Gy: A Novel De-escalation Paradigm for HPV-Associated Oropharynx Cancers Treated With Concurrent Chemoradiation Therapy (2017) (3)
- PARP1/2 imaging with 18F-PARPi in patients with head and neck cancer (2019) (3)
- Detection and management of isolated lymph node recurrence in patients with PSA relapse. (2007) (3)
- Interim Analysis of a Prospective Validation of 2 Blood-Based Genomic Assessments (PPQ and NETest) to Determine the Clinical Efficacy of 177Lu-DOTATATE in Neuroendocrine Tumors (2022) (3)
- Long-Term Follow-up Confirms Durability of Single-Agent Brentuximab Vedotin As Pre-Transplant Salvage for Classical Hodgkin Lymphoma (2019) (3)
- Comparison of PSA, FDG-PET, and Prostate Cancer Working Group 2 (PCWG2) criteria to interpret apparent progression on first post-treatment bone scan. (2012) (2)
- The impact of systemic chemotherapy on testicular FDG activity in young men with Hodgkin’s lymphoma (2013) (2)
- KesnerDDG - a free cross-vendor community research tool for data driven gating/motion correction workflow (2019) (2)
- Ironclad: A randomized phase III study of ibrutinib (Ibr) or no consolidation following autologous hematopoietic stem cell transplantation (AutoHCT) for relapsed/refractory activated-B-cell (ABC) subtype diffuse large B-cell lymphoma (DLBCL). (2017) (2)
- Correlation of 18F-Fluoromisonidazole Positron Emission and Computed Tomography (18F-FMISO PET/CT) with Dynamic Contrast Enhanced Magnetic Resonance Imaging (DCE MRI) in Assessing Tumor Hypoxia in Head and Neck Cancer(HNC) Patients with Nodal Metastases (2009) (2)
- Effect of Brentuximab Vedotin Addition to Chemotherapy and Prognostic Factors in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Large Multi-Trial Analysis Based on Individual Patient Data (2021) (2)
- Post-treatment alterations in 18F-dihydrotestosterone (FDHT) and FDG PET/CT in metastatic castration-resistant prostate cancer (mCRPC) treated with cabozantinib. (2013) (2)
- Potential Impact of Consolidation Radiation Therapy for Advanced Hodgkin Lymphoma: A Secondary Modeling of SWOG S0816 with Receiver Operating Characteristic Analysis (2018) (2)
- Retrospective Analysis of Gemcitabine and Oxaliplatin (GemOx)-Based Treatment in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (2019) (2)
- Architecture of the outbred brown fat proteome defines regulators of metabolic physiology (2022) (2)
- Initial Results of a Phase II Study of Sequential Chemotherapy and Lenalidomide Followed By Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma (2018) (2)
- Evaluation of PET response to neoadjuvant therapy for patients with gastric and GEJ adenocarcinoma. (2014) (2)
- Prognostic value of total lesion glycolysis on pretreatment F-18 FDG PET/CT in patients with advanced NSCLC treated with nivolumab (2018) (2)
- Clinical Significance of Pulmonary Nodules Missed on Non-Breath-Hold PET/CT (2013) (2)
- Reply to A. Hüttmann et al (2010) (2)
- Comparison of FDG and FMISO uptakes and distributions in head and neck squamous cell cancer tumors (2021) (2)
- Noninvasive Assessment of Human Epidermal Growth Factor Receptor 2 (HER2) in Esophagogastric Cancer Using 89Zr-Trastuzumab PET: A Pilot Study (2022) (2)
- The Path to the Future: Education of Nuclear Medicine Therapeutic Specialists as Responsible Physicians (2019) (2)
- Utility of 18 F-FDG–PET/CT in Soft Tissue Sarcomas (2014) (2)
- First-in-Human Trial of Epichaperome-Targeted Positron Emission Tomography in Cancer Patients. (2020) (2)
- Multiparametric imaging of tumor hypoxia and perfusion with 18 F-FMISO dynamic PET in head and neck cancer (2017) (2)
- Urachal remnant metastasis detected on [68Ga] PSMA-11 PET/CT in an asymptomatic prostate cancer patient with biochemical recurrence (2021) (1)
- In situ histopathological correlation of FDG uptake by autoradiography of needle biopsy specimens obtained under PET-CT guidance (2014) (1)
- Incidental Breast Lesions Identified by 18F-Fluorodeoxyglucose- (2010) (1)
- Multimodality imaging using proton magnetic resonance spectroscopic imaging and 18F-fluorodeoxyglucose-positron emission tomography in local prostate cancer (2017) (1)
- Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma (2022) (1)
- Abnormal coronary vasomotor response to mental stress in patients with coronary artery disease (CAD) (1998) (1)
- Imaging cellular immunotherapies and immune cell biomarkers: from preclinical studies to patients (2022) (1)
- Evaluating 18F-16β-fluoro-5α-dihydrotestosterone (FDHT) and FDG PET as prognostic biomarkers for patients (pts) treated with abiraterone acetate (AA). (2014) (1)
- NEW PROGNOSTIC SCORE INCORPORATING MTV PREDICTS TREATMENT FAILURE IN ADVANCED HODGKIN LYMPHOMA (2021) (1)
- Potential impact of consolidation radiation therapy for advanced Hodgkin lymphoma: a secondary analysis of SWOG S0816 (2020) (1)
- Treatment response and clinical outcomes of well-differentiated high-grade neuroendocrine tumors to 177Lu-DOTATATE. (2021) (1)
- A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma (2019) (1)
- A phase I trial of sorafenib with whole brain radiotherapy (WBRT) in breast cancer patients with brain metastases and a correlative study of FLT-PET brain imaging to evaluate treatment response after WBRT sorafenib. (2014) (1)
- [89Zr]Zr-huJ591 immuno-PET targeting PSMA in IDH mutant anaplastic oligodendroglioma (2021) (1)
- FDG-PET for staging of rhabdomyosarcoma (2005) (1)
- 18FDG-PET With CT Scan Co-Registration for Radiation Treatment Planning of Lymphoma Patients (2007) (1)
- 18F-16β-fluoro-5α-dihydrotestosterone (FDHT) PET as a prognostic biomarker for survival in patients with metastatic castrate-resistant prostate cancer (mCRPC). (2012) (1)
- An International Survey of PET/CT Clinical Reporting (2019) (1)
- Prognostic Utility of Serum TARC, MDC, IL10, and Soluble CD163 Levels with Positron Emission Tomography (PET) Response-Adapted Therapy for Advanced-Stage Hodgkin Lymphoma (HL): a SWOG S0816 US Intergroup Correlative Study (2017) (1)
- Immuno-PET imaging of activation markers on antigen-specific CD4 T cells in a mouse model of melanoma (2019) (1)
- Metabolic tumor volume to predict event free survival in patients with relapsed/refractory HL treated with brentuximab vedotin-based salvage therapy. (2016) (1)
- Brown adipose tissue is not associated with cachexia or increased mortality in a retrospective study of patients with cancer. (2022) (1)
- Plenary 5: Analyzing Serial Hypoxia Images From 18FMISO-PET: Modeling Transient and Chronic Hypoxia (2006) (1)
- Nuclear Imaging Techniques for the Evaluation of TMLR (1999) (1)
- Pathologic correlation of 18F-16{beta}-fluoro-5{alpha}-dihydrotestosterone (FDHT) and FDG PET in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). (2014) (1)
- Staging FDG-PET versus bone marrow aspirate/biopsy for assessment of metastatic bone involvement by rhabdomyosarcoma (2014) (1)
- PREDICTIVE VALUE OF QUANTITATIVE 18 F‐FDG‐PET‐CT RADIOMICS ANALYSIS IN 174 PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA (2021) (1)
- Quantitative analysis of blood-borne 18F-FMISO metabolites in cancer patients by HPLC using an integrated high-sensitivity coincidence detector (2015) (1)
- Preoperative chemotherapy plus bevacizumab with early salvage therapy based on FDG-PET response in locally advanced gastroesophageal junction and gastric adenocarcinoma. (2013) (1)
- A patient with primary cardiac lymphoma. (2002) (1)
- Evaluating 18F-16B-fluoro-5α-dihydrotestosterone (FDHT) and FDG-PET as a measure of disease progression in metastatic castration resistant prostate cancer (mCRPC). (2013) (1)
- Six Cycles of ABVD and a Negative PET Scan Negates the Need for Radiologic Follow-up in Early Stage, Non-Bulky Hodgkin Lymphoma: MSKCC Retrospective Analysis (2011) (1)
- Preliminary Results of a Prospective Trial of IMRT Dose De-escalation to Gross Nodal Disease in Human Papillomavirus (HPV)-Positive Oropharyngeal Carcinoma (OPC) Based on Assessment of Tumor Hypoxia Using 18F-FMISO PET Imaging (2014) (1)
- KRAS mutation effects on the 2-[18F]FDG PET uptake of colorectal adenocarcinoma metastases in the liver (2020) (1)
- Postoperative PET/CT for detection of early recurrence (ER) after surgery for squamous cell carcinomas (SCC) of the oral cavity (OC). (2021) (1)
- Application of Community Detection Algorithm to Investigate the Correlation between Imaging Biomarkers of Tumor Metabolism, Hypoxia, Cellularity, and Perfusion for Precision Radiotherapy in Head and Neck Squamous Cell Carcinomas (2021) (1)
- F-18 FDG PET/CT for monitoring immunotherapy with PD-1 blockade in patients with advanced melanoma (2019) (1)
- 13. Jahreskongress SGNM, 13ème Congrès annuel SSMN (2013) (0)
- Majority of Transformed Lymphomas Have High SUVs on PET Scanning Similar to Diffuse Large B Cell Lymphoma (DLBCL). (2006) (0)
- Brown adipose tissue is associated with cardiometabolic health (2021) (0)
- Teaching Cases in Nuclear Oncology: Penile Cancer (2016) (0)
- Functional tumor volume measurement in Ga-DOTATATE PET-CT: Which method is correct? (2020) (0)
- Abstract P1-19-03: A phase I trial of sorafenib with whole brain radiotherapy (WBRT) in breast cancer patients with brain metastases and a correlative study of FLT-PET brain imaging in patients receiving WBRT with or without sorafenib (2019) (0)
- Can Metabolic Tumor Volume Further Risk Stratify Patients Eligible for Treatment Deintensification in the Newly Proposed HPV-Associated Oropharyngeal Cancer Staging System? (2015) (0)
- Phase and amplitude binning for 4D PET/CT imaging (2006) (0)
- FDG-PET/CT is superior to bone scan for detection of bone metastases from rhabdomyosarcoma at staging (2014) (0)
- T099: High efficacy and durability of second-line therapy with pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin in the phase II study for relapsed and refractory Hodgkin lymphoma (2022) (0)
- Molecular Imaging of Cancer: Receptors, Angiogenesis, and Gene Expression (2009) (0)
- Interventional nuclear medicine. (2021) (0)
- Integrated SPECT/CT improves certainty and accuracy of posttherapy 131I imaging in thyroid cancer patients (2007) (0)
- Teaching Cases in Nuclear Oncology: Multiple Myeloma (2016) (0)
- Long‐term outcomes of patients with limited‐stage ocular adnexal DLBCL treated with combined modality therapy in the rituximab era (2022) (0)
- Assessment of salivary gland function after 177Lu-PSMA radioligand therapy: Current concepts in imaging and management (2022) (0)
- Reply to M.E. Juweid et al (2010) (0)
- SUV repeatability measurements in sequential PET of lung and liver lesions (2012) (0)
- 2022 SNMMI Highlights Lecture: Oncology and Therapy, Part 2 (2021) (0)
- Impact of allogeneic hematopoietic cell transplantation on immune evasive mechanisms in relapsed refractory large B-cell lymphoma (2020) (0)
- Long-Term Prognostic Value of 82Rb PET/CT–Determined Myocardial Perfusion and Flow Reserve in Cancer Patients (2023) (0)
- Outcomes of Patients with Positive Interim Positron Emission Tomography (PET) Continuing ABVD in the Clinical Setting (2023) (0)
- Failure patterns by PSMA PET for recurrent prostate cancer after prostatectomy and salvage radiation. (2022) (0)
- Imaging HER2-positive metastatic esophagogastric cancer with 89Zr-trastuzumab PET and 18F-FDG PET. (2021) (0)
- PET-adapted salvage therapy for Hodgkin's lymphoma--authors' reply. (2015) (0)
- Assessing tumor response using lesion-specific number of iterations (2014) (0)
- Impact of 18F-Fluorodeoxyglucose positron emission tomography on management of cancer of unknown primary: systematic review and meta-analysis. (2021) (0)
- Commentary from the Editors of the Continuing Education Section. (2018) (0)
- Diagnostic Applications of Nuclear Medicine: Head and Neck Cancer (2016) (0)
- Comparison of 18FDG and 18FMISO uptakes and distributions in head and neck cancer tumors (2014) (0)
- Correction to: Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[18F]FDG PET/CT external beam radiation treatment planning in lung cancer V1.0 (2022) (0)
- Polyethylene Glycol 3350 (PEG 3350) as a Practical Vehicle for Rapid Reconstitution of PARPi-FL Formulations for Clinical Use (2022) (0)
- Compartmental kinetic modeling of dynamic 18FMISO PET data in clinical NSCLC (2015) (0)
- 2022 SNMMI Highlights Lecture: Oncology and Therapy, Part 2. (2023) (0)
- Abstract 979: Bcl-2 inhibitor enhances anti-androgen therapy induced regression of castration sensitive prostate cancer (2021) (0)
- Trial-in-Progress: Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma (NCT#03269669): SWOG S1608 (2021) (0)
- Teaching Cases in Nuclear Oncology: Head and Neck Cancer (2016) (0)
- Comparison of PSA, FDG-PET, and Prostate Cancer Working Group 2 (PCWG2) criteria to interpret apparent progression on first post-treatment bone scan. (2012) (0)
- Prognostic Value of 18F-FDG PET/CT in Diffuse Large B-Cell Lymphoma Treated with a Risk-Adapted Immunochemotherapy Regimen (2022) (0)
- Evaluation of Dual Tracer (FLT and FDG) PET Imaging As Part of Risk-Adapted Therapy for Patients with Advanced Stage Diffuse Large B Cell Lymphoma (DLBCL) (2012) (0)
- Rest and stress 82Rb PET myocardial perfusion imaging as a predictor of perioperative cardiac events in cancer patients (2015) (0)
- Assessment of tumor microenvironment using DCE MRI and 18Fluoromisonidazole PET imaging in neck nodal metastases (2009) (0)
- A Pilot Study Of Using Pre- And Early (1 Week) [18f]-misonidazole Positron Emission And Computed Tomography (18F-FMISO PET/CT) Scans As An Early Treatment Response Predictor In A Series Of Head and Neck Cancer (HNC) Patients Undergoing Chemoradiation (2011) (0)
- Clinical significance of missed lung nodules on non-breath-hold PET/CT (2011) (0)
- [18F]-Fluorocholine Uptake Correlates with Pathologic Evidence of Recurrent Tumor After SRS for Brain Metastases (2016) (0)
- Detecting CXCR4 Expression in Meningioma on 68Ga-Pentixafor PET/MRI (2022) (0)
- Harnessing imaging tools to guide immunotherapy trials: summary from the National Cancer Institute Cancer Imaging Steering Committee workshop. (2023) (0)
- Qualification of FDG PET/CT as an oncologic biomarker: A methodology demonstration for lymphoma (2012) (0)
- Poorly Differentiated Thyroid Carcinoma (2014) (0)
- Poster ViewingA Pilot Study of Cardiac13N-Ammonia PET Imaging to Assess Early Cardiotoxicity Following Multibeam Intensity-Modulated Radiation Therapy for Breast Cancer (2017) (0)
- PET imaging in renal and bladder cancers (2022) (0)
- Favorable Outcomes of Patients with Limited-Stage Ocular Adnexal DLBCL Treated in the Rituximab Era: Long-Term Follow-up of a Single Center Experience (2021) (0)
- 2022 SNMMI Highlights Lecture: Oncology and Therapy, Part 1. (2022) (0)
- Chapter 8 – Lymphoma (2018) (0)
- To scan or not to scan? The value of radiologic surveillance in early-stage Hodgkin lymphoma (2013) (0)
- Prognostic Significance Of FDG-PET Metrics In Esophageal Squamous Cell Carcinoma (2014) (0)
- Teaching Cases in Nuclear Oncology: Thyroid Tumors (2016) (0)
- A New Arrow in the Prognostic Quiver for Heart Failure Patients (2010) (0)
- Positron Emission Tomography–Adapted Therapy in Bulky Stage I/II Classic Hodgkin Lymphoma: CALGB 50801 (Alliance) (2022) (0)
- The PCCTC imaging data capture toolset: An analysis of its impact on prostate cancer clinical trial accuracy and workload. (2011) (0)
- PET myocardial imaging with synthetic branched chain amino acid anti-1-amino-3-[18F]fluorocyclobutyl-1-carboxylic acid (18FACBC) (2006) (0)
- Is local review of positron emission tomography scans sufficient in diffuse large B‐cell lymphoma clinical trials? A CALGB 50303 analysis (2023) (0)
- TriDFusion (3DF) image viewer (2022) (0)
- Evaluating changes in tumor uptake of [18F]-FLT in patients with diffuse large cell lymphoma pre and post chemotherapy (2010) (0)
- HPV-Positive Oropharyngeal Cancers: Midtreatment PET During Radiation Therapy and Implications for Treatment De-escalation (2014) (0)
- Impact of interim PET on Hodgkin lymphoma treatment outcome and survival in clinical practice. (2020) (0)
- Validation of the International Harmonization Project (IHP) Guidelines in Early Stage Hodgkin Lymphoma (HL) Treated with Adriamycin, Vinblastine and Gemcitabine (AVG) (CALGB 50203): Early Results. (2008) (0)
- Post-operative PET/CT improves the detection of early recurrence of squamous cell carcinomas of the oral cavity. (2023) (0)
- Reproducibility of SUVmax in serial PET studies (2009) (0)
- A Multi-Institutional Biomarker Study of Large B-cell Lymphomas in FDG PET/CT - Experiences within the Oncology Biomarker Qualification Initiative (OBQI) (2016) (0)
- Local Review Versus (vs) Central Review of Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) in Diffuse Large B-Cell Lymphoma (DLBCL): Results from the CALGB 50303 Trial [Alliance] (2020) (0)
- A Case-Based Approach to PET/CT in Oncology: Head, neck, and thyroid (2012) (0)
- Quantitative Change in Metabolic Tumor Volume May Assist in Distinguishing between Pseudoprogressors and Responders in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma Treated with PD-1 Blockade (2021) (0)
- 1H-MRS and 18FDG PET: Metabolism in head and neck cancers (2009) (0)
- Phase II study of preoperative chemotherapy plus bevacizumab with early salvage therapy based on FDG-PET response in patients with locally advanced gastric and GEJ adenocarcinoma. (2013) (0)
- Kinetic analysis of 18F-FMISO dynamic PET using shortened datasets (2015) (0)
- Preliminary clinical studies with the tumor hypoxia PET tracer 124I-IAZGP (2007) (0)
- 16 INVITED Imaging of Hypoxia With PET Radiotracers, Including, Ca-IX Antibodies (2011) (0)
- Fluorodeoxyglucose (FDG) PET as an outcome measure for metastatic prostate cancer. (2010) (0)
- Comparison of immediate post-ablation PET/CT and contrast enhanced CT as predictors of local tumor progression within one year of treatment (2015) (0)
- Nuclear Oncology Teaching Cases (2013) (0)
- Teaching Cases in Nuclear Oncology: Parathyroid Tumors (2016) (0)
- changes in management, volume definition, and normal tissue dosimetry for many patients. A prospective trial is now underway to further characterize the impact of PET/CT in treatment planning for lymphoma patients. (2007) (0)
- Diagnostic and Prognostic Utility of 18F-FDG PET/CT in Recurrent Salivary Gland Cancers. (2021) (0)
- Correction to: [89Zr]Zr‑huJ591 immuno‑PET targeting PSMA in IDH mutant anaplastic oligodendroglioma (2022) (0)
- P107: Effect of Brentuximab Vedotin Addition to Chemotherapy and Prognostic Factors in Patients with Relapsed/Refractory Hodgkin Lymphoma: a Large Multi-Trial Analysis Based on Individual Patient Data (2022) (0)
- Prognostic value of 18F-FDG PET/CT Imaging in Recurrent Salivary Gland Cancers (2019) (0)
- Teaching Cases in Nuclear Oncology: Testicular Cancer (2016) (0)
- PARP imaging with 18F-PARPi in patients with head and neck cancer (2020) (0)
- Perioperative chemotherapy plus bevacizumab with early salvage therapy based on PET response in patients with locally advanced resectable gastric/GEJ cancer. (2010) (0)
- SU-E-J-263: Repeatability of SUV and Texture Parameters in Serial PET Studies (2015) (0)
- P004: Advanced stage classical Hodgkin lymphoma (cHL) patients with a positive interim-PET (PET-2) Deauville score (DS) 5 after 2 ABVD cycles: A pooled analysis of individual patient data of three multicenter trials (2022) (0)
- CLINICAL OUTCOMES AND THE ROLE OF OBSERVATION IN EARLY‐STAGE FOLLICULAR LYMPHOMA (2021) (0)
- Fluorodeoxyglucose (FDG) positron emission tomography (PET) as an indicator of disease progression for patients with castration-resistant metastatic prostate cancer (CRMPC). (2011) (0)
- The Geriatric Syndrome of Sarcopenia Impacts Allogeneic Hematopoietic Cell Transplantation Outcomes in Combination with Multi-Morbidity and Functional Impairment (2019) (0)
- Chapter 10 – Prostate Cancer (2018) (0)
- 2021 SNMMI Highlights Lecture: Oncology and Therapy, Part 1. (2021) (0)
- No need for routine radiologic surveillance in early stage Hodgkin lymphoma (HL) treated with combined ABVD and radiotherapy (2014) (0)
- Paediatric bone sarcoma: FDG-PET/CT vs. conventional imaging. A collaborative study (2013) (0)
- Teaching Cases in Nuclear Oncology: Lymphomas (2016) (0)
- 23-4 Gender differences in effect of mental stress on myocardial blood flow: A quantitative PET study (1997) (0)
- Significance of targeting the antiapoptotic pathway in castration-sensitive prostate cancer. (2021) (0)
- Primary Tumor Metabolic Volume Improves Risk Prediction of Long-term Outcomes in Patients with Oropharyngeal Squamous Cell Carcinoma Treated with Intensity Modulated Radiation Therapy (IMRT) and Chemotherapy (2011) (0)
- Reproducibility of 18FMISO PET kinetic parameters in NSCLC (2014) (0)
- PET imaging of recurrent brain tumors using 18F-FACBC (2019) (0)
- Interim Positron Emission Tomography During Frontline Chemoimmunotherapy for Follicular Lymphoma (2023) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Heiko M. Schöder?
Heiko M. Schöder is affiliated with the following schools:
